All Posts

We are contacting you about the recent Alfamino Infant Formula recall . Alfamino is a specialist infant formula for babies with allergies or gastrointestinal disorders. It is largely a prescribed product and is not available in supermarkets. The affected batches of Alfamino Infant Formula are: Batch number 51070017Y2, use-by date 17.04.2027 Batch number 51080017Y1, use-by date 18.04.2027 Batch number 51480017Y3, use-by date 28.05.2027 Batch number 51490017Y1, use-by date 29.0

In this study of 200 patients with recurrent AF, patients were randomly assigned in a 1:1 ratio to either regular caffeinated coffee consumption or complete abstinence from coffee and caffeine for 6 months 1 . The consumption group was encouraged to drink at least one cup daily, while the abstinence group avoided all caffeinated and decaffeinated coffee and other caffeine products. Baseline intake was 7 cups per week in both groups. During follow-up, the median intake was 7 (

Looking for a new challenge? We are seeking a passionate Registered Nurse to support the development of New Zealand nursing procedures.  Lippincott is offering a part-time, work-from-home, flexible, freelance clinical editor role.   Please see job description attached.

Position : Nurse Practitioner Location : Nelson New Zealand About Us Cannabis Clinic have been embarking on a groundbreaking mission to revolutionise healthcare, and we're inviting you to join us on this exhilarating journey of reinventing what it truly means to care for health. From redefining the essence of health to reimagining the significance of care in healthcare, we're committed to reshaping the experience of both our patients and our team members. we're not just chang

The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 (the Regulations) set the minimum quality standard that medicinal cannabis products and ingredients must meet before they can be supplied in New Zealand. Importers, manufacturers, and suppliers must apply for assessment and provide evidence to the Medicinal Cannabis Agency to verify that their products meet the minimum quality standard. Bloom Blue Dream has been verified as meeting the minimum quality standard. White S

Alfacalcidol (One-Alpha) oral drops 2 mcg/ml and cap 0.25 mcg  (Pharmacode 315761 & 203084) Due to a shipping delay and increased demand, Link (the supplier) is out of stock of the oral drops and has limited supply of the 0.25 mcg presentations of alfacalcidol. Ferrous fumarate (Ferro-Tab) (Pharmacode 2162156) Due to the discontinuation of another iron supplement product, there is constrained supply of the Ferro-Tab brand. Hydroxocobalamin (B12) inj 1 mg per ml (Pharmacode

Discontinuation:   We are writing to inform you that NovoNordisk are rationalising their product range and discontinuing four insulins. Please begin transitioning your patients to suitable alternatives.   Key Dates: PenMix30 Penfill 3ml Supply of the PenMix30 ended October 2025. The remaining stock expires in April 2026. This will be delisted (no longer funded) 1 May 2026. Please see advice:  NZSSD Guidance: Discontinuation of Penmix30 and Penmix50 and Mixtard 30 , July 2024.

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 19 December 2025. It includes information on:  New updates Resolved Supply Issues New listing: aripiprazole 300 mg and 400mg injection (Abilify Maintena) Abilify Maintena can now be administered by intramuscular injection into either the gluteal or deltoid muscle. The previous packaging did not include the extra needle to use for deltoid administrat

We understand that there are concerns about the efficacy and adhesion of some batches of Estradot (oestradiol) patches. Medsafe have been investigating the concerns raised.   Information about the Medsafe process can be found here:   Information from the supplier of Estradot, Sandoz can be found here:      We have sent communications to consumer groups advising: Pharmac is responsible for the funding of medicines, while Medsafe assesses medicines to ensure they meet internati

Nurse Practitioner – Full or Part Time Residential Eldercare Services   🌟 Join Our Exceptional Team as a Nurse Practitioner! 🌟 Are you passionate about providing the highest standard of care to the elderly? Do you thrive in a collaborative and supportive work environment? We have an exciting job opportunity for Nurse Practitioners to join our unique totally mobile general practice dedicated to eldercare. At Residential Eldercare Services, we believe in fostering a dynamic a

Kia ora koutou As we approach the end of the year, I want to take a moment to acknowledge the significant work happening across the country to support the mental health and wellbeing of our communities. This time of year can bring both opportunities for rest and connection, and additional challenges for some people, whānau and communities. Our role at the Ministry of Health supports and strengthens the work happening across the health system. The advice we provide and the fra

Supply issue:   We are writing to inform you that due to difficulty sourcing the active ingredient, the delivery of Zincaps into NZ will be further delayed    Key messages: Resupply of the Medsafe approved Zincaps is not expected until late February 2026. An alternative Section 29 Zincaps was listed 1 October 2025, and this stock has now been depleted. A second Section 29 alternative product will be listed (funded) and available from 1 January 2026. This alternate product is

Kia ora koutou As we approach the end of the 2025, I want to acknowledge the dedicated and hard-working health workforce, who have worked tirelessly across the country to improve health outcomes for all New Zealanders. While our health system faces challenges, good progress has been made this year in a range of areas that are key to improving New Zealanders' health outcomes. This week’s reporting against health targets highlights some of this progress. Key improvements for

Ministry of Health update on puberty blockers On 4 December we provided an update on the Government’s regulations for puberty blocker prescribing which were announced on 19 November 2025 and published online on the Legislation New Zealand website: · Medicines (Restriction on Prescribing Gonadotropin-releasing Hormone Analogues) Amendment Regulations 2025   The regulations take effect from tomorrow, 19 December 2025 . After this date, new prescriptions for GnRH analogues for t

The brand of varenicline tab 0.5 mg and 1 mg starter pack and varenicline tab 1 mg continuation pack  is changing from Champix (supplied by Pfizer) to Pharmacor Varenicline.   Pharmacor Varenicline tab 0.5 mg x 11 and 1 mg x 42 starter pack and varenicline tab 1 mg x 56 continuation pack will be listed in the community and hospital schedules from 1 January 2026.   Pharmacor Varenicline will have Principal Supply Status from 1 June 2026 and Champix will be delisted.   What is

Kickstart the New Year with a Nurse Practitioner role in the location you love! Step into the year ahead with a fresh role that brings renewed purpose to your nursing career. Start the next chapter of your medical journey with Third Age Health, New Zealand’s leading and most trusted provider of general practice healthcare in Aged Residential Care. Together, we can deliver meaningful, person-centred care to older adults across the country. We’re expanding our team nationwide a

In this RCT, 382 children aged 5-15 years with asthma using budesonide 50 μg-formoterol 3 μg, two actuations as needed, equivalent to 1 puff Symbicort 100/6 or Vannair 100/6, were compared to salbutamol 100 ug as needed. 1 The primary outcome was asthma attacks as rate per participant per year. The annualised rate of asthma attacks was lower in the budesonide-formoterol group than in the salbutamol group, cluster-adjusted rates 0·23 versus 0·41 per participant per year (rela

Pharmac is calling for new funding applications for medicines for rare disorders ahead of our Rare Disorders Advisory Committee meeting. We know that people with rare disorders face challenges including access to suitable health care and accessing effective medicines. We are committed to a regular call for applications for medicines for rare disorders. We are asking for new applications from pharmaceutical suppliers so we can consider taking them to our next meeting on  Wedne

Following feedback, Pharmac has decided not to proceed with a proposal to decline some low-ranked applications on the Options for Investment (OFI) list. We heard from a wide range of people - clinicians, professional groups, patient advocates, individuals and pharmaceutical companies. People told us that while they understood our aim was to improve transparency, they did not want us to remove funding applications from the OFI. We’ve listened carefully and appreciate the time

Kia ora   We are writing to inform you of two new listings:   aripiprazole 300 mg and 400mg injection (Abilify Maintena)   Key Date: Both of these products will be listed (funded) from 1 January 2026   Key messages: Abilify Maintena can now be administered by intramuscular injection into either the gluteal or deltoid muscle. The previous listed (funded) products did not include the extra needle to use for deltoid  administration. The package with needle for deltoid administra